Orchid Island Capital to Announce First Quarter 2021 Results

Orchid Island Capital to Announce First Quarter 2021 Results

VERO BEACH, Fla.–(BUSINESS WIRE)–
Orchid Island Capital, Inc. (NYSE:ORC) (“Orchid” or the “Company”), a real estate investment trust (“REIT”), today announced that it will release results for the first quarter of 2021 following the close of trading on the New York Stock Exchange on Thursday, April 29, 2021.

Earnings Conference Call Details

An earnings conference call and live audio webcast will be hosted Friday, April 30, 2021, at 10:00 AM ET. The conference call may be accessed by dialing toll free (833) 794-1168. International callers dial (236) 714-2726. The conference ID is 5156838. A live audio webcast of the conference call can be accessed via the investor relations section of the Company’s website at www.orchidislandcapital.com, and an audio archive of the webcast will be available until May 30, 2021.

About Orchid Island Capital, Inc.

Orchid Island Capital, Inc. is a specialty finance company that invests on a leveraged basis in Agency RMBS. Our investment strategy focuses on, and our portfolio consists of, two categories of Agency RMBS: (i) traditional pass-through Agency RMBS, such as mortgage pass-through certificates issued by Fannie Mae, Freddie Mac or Ginnie Mae and CMOS, and (ii) structured Agency RMBS. Orchid is managed by Bimini Advisors, LLC, a registered investment adviser with the Securities and Exchange Commission.

Orchid Island Capital, Inc.

Robert E. Cauley, 772-231-1400

Chairman and Chief Executive Officer

www.orchidislandcapital.com

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Construction & Property Professional Services REIT Finance

MEDIA:

Logo
Logo

Frontage Expands Genomics Services Through the Acquisition of Ocean Ridge Biosciences

PR Newswire

EXTON, Pa., April 19, 2021 /PRNewswire/ — Frontage Laboratories, Inc. today announced the acquisition of Ocean Ridge Biosciences.

Ocean Ridge Biosciences, located in Deerfield Beach, Florida, provides genomic services to clients developing novel therapeutics, including complete service solutions for analysis of RNA expression, DNA polymorphisms, methylation, microbial composition, and protein biomarkers from a wide range of samples. The company’s wet lab services are optimized for ultra-low input requirements and challenging sample types such as formalin-fixed paraffin-embedded tissues, skin swabs, and a variety of biofluids. Some of the core applications includes mechanism of action, lead optimization, biomarker discovery, and development of companion diagnostics.

“Ocean Ridge Biosciences was established more than 15 years ago, and was a very early adopter offering Next Gen Sequencing (NGS) services for exploiting RNA, mRNA and microRNA arrays for Biomarkers involved in the detection and treatment of diseases,” says Dr. John Lin, Executive Vice President, Bioanalytical and Biologics Services. “Ocean Ridge specializes in extraction and analysis of RNA and proteins from a wide variety of biological samples, using technologies including microarrays, sequencing, Luminex xMAP, real-time PCR platforms, and statistical analysis of data sets. We expect this acquisition to bolster Frontage’s current genomic services by enabling us to provide accurate, affordable, and information-rich genomic services to the Health Care and Life Science industries and academic institutions. We anticipate that the Ocean Ridge lab will retain its existing client base and will extend its offerings to new clients as it becomes a Frontage center of excellence in Genomic Services.”

David Willoughby, Founder and Senior Scientist at Ocean Ridge Bioscience, who is joining Frontage Labs as Vice President of Genomic Services, said “I am pleased to join the Frontage Labs team and bring with me the unique set of genomic services developed by Ocean Ridge, which will now be available to an even broader range of therapeutic programs and pharmaceutical industry clients both in the United States and worldwide. Ocean Ridge Bioscience’s services will complement the wide variety of IND-enabling and clinical-trial related services offered by Frontage Labs, including their services for protein-, oligonucleotide-, gene-, and cell-based therapeutic discovery and development.”

About Frontage (www.frontagelab.com)

Frontage Holdings Corp (1521.HK), together with its wholly owned subsidiary Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) which provides integrated, science-driven, product development services from drug discovery to late phase clinical process to enable biopharmaceutical companies to achieve their development goals.  Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions.  For more details visit: www.frontagelab.com

About Ocean Ridge Biosciences (www.oceanridgebio.com)

Ocean Ridge Biosciences is a growing life science company in the research tools sector of biotechnology whose mission is to provide accurate, affordable, and information-rich genomic services to the Health Care and Life Science industries. Headquartered in Deerfield Beach, they are centrally located within the South Florida metropolis within easy reach of major research universities, institutes, and hospitals. Demand for high quality genomic services is steadily increasing for both research and clinical applications. Ocean Ridge Biosciences is capitalizing on that growth due to our capability of providing these services at attractive pricing in combination with excellent customer service.

Contact:

Bryan Newman

+1.610.232.0100
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/frontage-expands-genomics-services-through-the-acquisition-of-ocean-ridge-biosciences-301271442.html

SOURCE Frontage Laboratories, Inc.

Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects

PR Newswire

ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/ — Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced findings of pre-clinical research demonstrating that Ampio’s lead drug candidate, Ampion™, provides some of the same anti-inflammatory effects as the steroid dexamethasone but without the significant adverse events associated with steroids.

“Steroids such as dexamethasone are globally immunosuppressive, to both innate and adaptive immune systems, with effects that are beneficial in the short term and often harmful long-term,” said David Bar-Or, M.D., Director and Founder of Ampio Pharmaceuticals.

“Our research looked at the gene-level interactions of both Ampion and dexamethasone in immunostimulated peripheral blood monocytes, or PBMCs,” continued Bar-Or, “and it became clear that Ampion regulated some of the same inflammation-associated genes as dexamethasone, though through disparate mechanisms of action. This may explain Ampion’s ability to mimic the anti-inflammatory effects of steroids without causing similar adverse effects.”

Michael Macaluso, President and CEO of Ampio, commented, “The coronavirus pandemic has highlighted the critical need for medical innovation. The potential availability of an anti-inflammatory therapy that provides many of the same benefits of dexamethasone without the similar adverse effects of long-term use would be a boon for patients suffering from debilitating and often life-threatening inflammatory disease.”

The research highlighted key similarities and differences between Ampion and dexamethasone.

Similarities
between Ampion and Dexamethasone

In the three different immunostimulation conditions used to evaluate Ampion’s effect on PBMCs, Ampion regulated 102 of the same transcripts as dexamethasone according to RNA sequencing and differential gene expression analysis performed with Ingenuity Pathway Analysis (IPA) software from QIAGEN Digital Insights.

Further, overall IPA modeling predicted significantly similar regulation of downstream molecules by dexamethasone and Ampion based on directionally correlated transcripts. A comparison showed that, in each immunostimulatory condition, transcripts regulated by Ampion significantly overlapped with transcripts regulated by dexamethasone.

“Ampion acts as an anti-inflammatory drug with some important overlapping effects also provided by dexamethasone,” explained Bar-Or.

Differences between Ampion and Dexamethasone

However, there were some significant differences seen between Ampion and dexamethasone. Based on IPA computational modeling, there were 30 transcripts where Ampion’s activity was different than known regulation by dexamethasone – up regulating when dexamethasone was down, or vice versa – in at least one of the treatment conditions. Dexamethasone also targets a wide range of molecules that are not regulated by Ampion.

“These observations may help to explain, in addition to the different modes of action of the two drugs, why patients treated with Ampion do not suffer the same adverse effects as those treated with dexamethasone,” said Bar-Or.

The absence of significant adverse effects in the large numbers of patients administered Ampion – by intra-articular injection, intravenous administration, and inhalation, and now supported by multi-omics (genomics, transcriptomics, proteomics and metabolomics) analysis and IPA modeling of the Mechanism of Action (MOA) of Ampion compared to corticosteroids, provides an encouraging foundation for the ongoing clinical investigations of Ampion in a wide range of inflammatory conditions.

“In essence,” concluded Bar-Or, “this evidence suggests that Ampion is an anti-inflammatory drug with some important overlapping effects provided by dexamethasone but without the significant adverse events associated with steroids.”

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio’s lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2035 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).

Forward Looking Statements

Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts

Investor Relations

Joe Hassett

[email protected]

484-686-6600

Media Contact

Katie Kennedy

[email protected]

610-731-1045

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/research-shows-ampion-gene-regulation-mimics-the-anti-inflammatory-effects-of-steroids-but-without-adverse-effects-301271077.html

SOURCE Ampio Pharmaceuticals, Inc.

Zynex Schedules 2021 First Quarter Earnings Call

PR Newswire

ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/ — Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company’s 2021 first quarter earnings investor webcast on Thursday, April 29, 2021 at 2:15 p.m. Mountain Time (4:15 p.m. Eastern Time.)

Webcast Details: Thursday, April 29, 2021 at 2:15 p.m. MT / 4:15 p.m. ET

To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast:

https://www.webcaster4.com/Webcast/Page/1487/40947


US PARTICIPANT DIAL IN (TOLL FREE):

1-844-825-9790


INTERNATIONAL DIAL IN:

1-412-317-5170


Canada Toll Free:

1-855-669-9657

About Zynex 

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the Company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex has also developed a blood volume monitor for use in hospitals and surgery centers.  For additional information, please visit: Zynex.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements.  The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including, but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:

Zynex, Inc.
(800) 495-6670

Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/zynex-schedules-2021-first-quarter-earnings-call-301271075.html

SOURCE Zynex

Mapbox Launches Dash: Beautiful In-car Navigation, Live Traffic, Streaming Music All-in-one Application

Mapbox Launches Dash: Beautiful In-car Navigation, Live Traffic, Streaming Music All-in-one Application

Enables car makers to fully own location experience by offering customization options

General Motors first car maker to adopt Mapbox Dash through app-based in-car navigation system, Maps+

SAN FRANCISCO–(BUSINESS WIRE)–
Mapbox today announced the launch of Mapbox Dash, a customizable lane level navigation system for cars. Dash allows automakers to control every aspect of the navigation experience, including the map and UI design, and offers lane level guidance, live traffic, speed limit warnings, voice integration, rich places search, AR navigation, mobile integrations and more. It supports integrations into custom services like parking, fuel, AI assistants, and streaming music. Mapbox Dash is available to car makers as a subscription service with continuous feature updates throughout the lifetime of the application.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005516/en/

Customized versions of Mapbox Dash. (Graphic: Business Wire)

Customized versions of Mapbox Dash. (Graphic: Business Wire)

“With Mapbox Dash, we are delivering the best of both worlds for our customers: an integrated application with an excellent and fast ‘out of the box’ experience for Android and Linux, and a customization option through the Mapbox platform to create a unique OEM brand experience aligned with drivers’ needs. We believe great applications are built around customer feedback, and our team is continuously updating Dash with frequent new releases that incorporate driver feedback and ensure we are offering the most up-to-date and personalized platform to our customers,” – said Peter Sirota, Mapbox CEO.

General Motors (“GM”) is the first car maker to adopt Mapbox Dash through the launch of its Maps+, a connected in-car navigation application built on Mapbox Dash. On April 30, Maps+ is expected to begin its rollout to approximately 900,000 compatible vehicles as part of select Connected Services plans. For the rollout, drivers will be able to upgrade their existing vehicle to include a full featured in-car navigation system with a simple over the air software update.

“Mapbox Dash delivers an efficient and smooth customizable foundation for our digital location ecosystem and enabled us to launch Maps+ within months with an over-the-air update to the car. With Mapbox Dash we can create a customized navigation experience, by creating a completely GM specific design and integrating a vehicle-specific voice assistant, streaming music, and other services,” said Santiago Chamorro, Vice President, Global Connected Services at GM.

GM will launch an initial version with a distinct look and feel for their Chevrolet, Buick, GMC and Cadillac brands. The navigation system will include lane level guidance, live traffic and incidents, Electronic Horizon for speed limit alerts, Alexa integration, rich POI search with ratings, pictures, and opening times. The application suggests gas stations when the car is running low on fuel and finds parking at the destination with a tap on the parking button. The search function stores favorite destinations and past destinations on drivers’ private accounts reducing starting a trip to known destinations to few taps on the screen. A convenient widget on top of the map offers audio controls for direct access to audio apps and FM/AM.

Mapbox Dash – Built on the Mapbox Platform

Mapbox Dash’s one-of-a-kind architecture allows car makers to quickly launch and integrate vehicle-specific functions. This reduces the launch time of new applications — from discovery session to customer release — to as fast as only a few months. Mapbox Dash accomplishes this by building on top of the Mapbox Platform with its highly modular architecture of Mapbox SDKs used by hundreds of thousands of developers. Dash implements on top of this platform an application layer that can be customized to each car maker, their brands and specific model lines such as EV, offroad, performance, and family vehicles. In addition, the Dash application can be combined with full custom software build outs based on Mapbox.

===

About Mapbox

Mapbox powers location across all major industries. Millions of hardware and software developers use Mapbox to add live location awareness including maps, navigation, and search services to mobile and web applications, logistics and dispatching and in-car automotive navigation.

The Mapbox AI-powered data pipeline processes over 300 million miles of anonymized and aggregated live road telemetry data daily allowing Mapbox to continuously update the map everywhere in the world.

Founded in 2010 in a garage in Washington, D.C., Mapbox now has more than 600 million monthly active users touching its maps, a global team of more than 500 employees, and is used by industry leaders including General Motors, Instacart, Adobe, CNN, IBM, Strava, The New York Times, Snapchat, Square, The Weather Channel, Lonely Planet, Mastercard, The United Nations, Tableau, and Microsoft Power BI. Learn more at www.mapbox.com.

About GM

General Motors (NYSE:GM) is a global company focused on advancing an all-electric future that is inclusive and accessible to all. At the heart of this strategy is the Ultium battery platform, which powers everything from mass-market to high-performance vehicles. General Motors, its subsidiaries and its joint venture entities sell vehicles under the Chevrolet, Buick, GMC, Cadillac, Baojun and Wuling brands. More information on the company and its subsidiaries, including OnStar, a global leader in vehicle safety and security services, can be found at https://www.gm.com.

Savannah Polzin

Mapbox Communications

303-819-6182

[email protected]

Stephanie Obendorfer

GM Communications

313-400-7540

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Automotive General Automotive Technology Other Automotive Software Hardware

MEDIA:

Photo
Photo
Customized versions of Mapbox Dash. (Graphic: Business Wire)
Photo
Photo
GM’s Maps+ application built on Mapbox Dash. (Graphic: Business Wire)
Photo
Photo
(Graphic: Business Wire)

Mastercard to Acquire Ekata to Advance Digital Identity Efforts

Mastercard to Acquire Ekata to Advance Digital Identity Efforts

New Capabilities Strengthen Trust in Every Interaction Through AI-Powered Identity Verification Reinforced By Commitment to Strong Data Management Principles

PURCHASE, N.Y.–(BUSINESS WIRE)–
Trust is the key ingredient to conducting digital commerce. Central to creating trust in a digital world is the ability to prove your digital identity – who you are, whether you are interacting in person, online or in app.

Today, Mastercard (NYSE: MA) took steps to advance its identity verification efforts with the acquisition of Ekata for US$850 million.

Digital identity is a foundational part of Mastercard’s multi-layered approach to security. In 2019, the company introduced a new framework on how digital interactions should evolve, as well as how digital identity will build trust, collaboration and economic growth. That framework is now in use across a number of sectors, from education to travel to healthcare.

Ekata works with a wide range of global merchants, financial institutions, travel companies, marketplaces and digital currency platforms. The company uses insights to deliver unique scores, data attributes and risk indicators that businesses then use to make more informed decisions. They help their customers identify good consumers and businesses and bad actors in real-time during online account opening, payments and variety of other digital interactions.

“The shift to a more digital world requires real solutions to secure every transaction and instill trust in every interaction,” said Ajay Bhalla, president of cyber and intelligence solutions at Mastercard. “With the addition of Ekata, we will advance our identity capabilities and create a safer, seamless way for consumers to prove who they say they are in the new digital economy.”

Ekata’s identity verification data, machine learning technology and global experience combined with Mastercard’s fraud prevention and digital identity programs will help businesses confidently know who their customers are and, in turn, help those customers safely interact online. Mastercard and Ekata’s integrated services will build on both companies’ commitments to ensure trust and the responsible use of data.

“The acceleration of online transactions has thrust global digital identity verification to the forefront as one of the biggest opportunities to build digital trust and combat global fraud,” said Rob Eleveld, CEO at Ekata, Inc. “The right identity verification solutions enable inclusive and frictionless experiences while, at the same time, ensuring customer privacy, control and security. Becoming part of the Mastercard Identity family ensures a broader, collective approach to meeting the growing demands of the digital economy.”

Ekata is headquartered in Seattle, with offices in Amsterdam, Singapore and Budapest.

Delivering on the Strategy, Strengthening Value

Commitment to Privacy, Responsibility – Ekata shares Mastercard’s commitment to safe and secure data practices centered around the individual, further reinforcing their value to the end user.

Strong Identity Technology – Ekata has built a core set of identity verification services that helps to provide the backbone of the safety and security of everyday commerce. By bringing the capabilities, technologies and teams together, there is the potential to deliver even more trust and peace of mind, well beyond identity verification and identifying fraud trends.

Complementary Expertise – The addition of Ekata’s technology and engineering teams will help bolster the support Mastercard can provide as a one-stop partner for any consumer, bank, merchant, fintech or government’s data, payment and open banking needs. The combined capabilities across digital-first, installment and crypto payment services will help to enable greater choice and functionality, with the potential to expand further to real-time payments and cross-border activities.

Together, Mastercard and Ekata will deliver a more comprehensive identity service that can power real-time decision-making needs, from new account openings to helping merchants assess potential fraud before a payment transaction is authorized.

As with past acquisitions, Mastercard does not expect this acquisition to be dilutive to its business for greater than 24 months. This dilution is driven by investments in the business, including the impact of purchase accounting and integration related costs.

The transaction is subject to regulatory review and customary closing conditions. It is anticipated to close within the next six months.

About Mastercard

Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments and businesses realize their greatest potential. Our decency quotient, or DQ, drives our culture and everything we do inside and outside of our company. With connections across more than 210 countries and territories, we are building a sustainable world that unlocks priceless possibilities for all. www.mastercard.com

About Ekata

Ekata Inc, is the global leader in digital identity verification solutions that provide businesses worldwide the ability to link any digital transaction to the human behind it. The Ekata product suite is powered by the Ekata Identity Engine, comprised of two proprietary data sets ­— the Ekata Identity Graph and the Ekata Identity Network. Ekata’s global suite of APIs and SaaS solutions help 2,000+ businesses and partners combat cyberfraud and enable an inclusive, frictionless experience in over 230 countries and territories.

Forward-Looking Statements

This press release contains forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts may be forward-looking statements. When used in this press release, the words “believe,” “expect,” “could,” “may,” “would,” “will,” “trend” and similar words are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements that relate to Mastercard’s future prospects, developments and business strategies, as well as Mastercard’s acquisition and operation of Ekata. We caution you to not place undue reliance on these forward-looking statements, as they speak only as of the date they are made. Except for the company’s ongoing obligations under the U.S. federal securities laws, the company does not intend to update or otherwise revise the forward-looking information to reflect actual results of operations, changes in financial condition, changes in estimates, expectations or assumptions, changes in general economic or industry conditions or other circumstances arising and/or existing since the preparation of this press release or to reflect the occurrence of any unanticipated events.

Many factors and uncertainties relating to the proposed transaction, our operations and our business environment, all of which are difficult to predict and many of which are outside of our control, influence whether any forward-looking statements can or will be achieved. Any one of these factors could cause our actual results or the impact of the acquisition to differ materially from those expressed or implied in writing in any forward-looking statements made by Mastercard or on its behalf. Such factors related to the completion and impact of the acquisition include, but are not limited to, whether all necessary conditions will be met, and whether the transaction will close on agreed terms and in a timely manner.

For additional information on other factors related to Mastercard’s overall business that could cause Mastercard’s actual results to differ materially from expected results, please see the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K for the year ended December 31, 2020, and any subsequent reports on Forms 10-Q and 8-K.

Mastercard Investor Relations: Gina Accordino, [email protected], 914-249-4565

Mastercard Communications: Seth Eisen, [email protected], 914-249-3153

Ekata: Beth Shulkin, [email protected], 206-679-2983

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Data Management Security Technology Finance Networks Banking

MEDIA:

Logo
Logo

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against MOGU Inc. and Encourages Investors With Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against MOGU Inc. and Encourages Investors With Losses of $100,000 to Contact the Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MOGU Inc. (“MOGU” or “the Company”) (NYSE: MOGU) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. MOGU disclosed its unaudited financial results for the third quarter of fiscal year 2021 on February 25, 2021. The Company stated: “Commission revenues decreased by 29.8% to RMB99.2 million (US$15.2million) from RMB141.2million in the same period of fiscal year 2020, primarily due to the restructuring of the Company’s business towards a LVB-focused model,” and that “Marketing services revenues decreased by 75.9% to RMB17.4 million (US$2.7million) from RMB72.5 million in the same period of fiscal year 2020 … primarily due to the restructuring of the Company’s business towards a LVB-focused model,” and that “other revenues decreased by 46.4% to RMB29.9 million (US$4.6million) from RMB55.9 million in the same period of fiscal year 2020, primarily due to a decrease in online direct sales.” The Company also reported a loss from operations of RMB123.2 million, “primarily attributable to a goodwill impairment incurred in the third quarter of fiscal year 2020.” Based on this news, MOGU’s ADR price fell by 17% over the next several trading sessions.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm

Brian Schall, Esq.

310-301-3335

[email protected]

www.schallfirm.com

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented at American Academy of Neurology (AAN) Annual Meeting

Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented at American Academy of Neurology (AAN) Annual Meeting

TUCSON, Ariz. & EMERYVILLE, Calif.–(BUSINESS WIRE)–
Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced findings from a survey on the impact of OFF time and dyskinesia, also known as Parkinson’s disease (PD) motor complications, presented at the American Academy of Neurology (AAN) Annual Meeting, by Jill Farmer, D.O., M.P.H.. The survey, co-sponsored by PMD Alliance and Adamas Pharmaceuticals, was conducted by PMD Alliance, and the results were based on 775 respondents, including 527 people with Parkinson’s and 248 care partners.

“These survey findings highlight what I’ve consistently seen in my practice treating people with Parkinson’s disease,” said Jill Giordano Farmer, D.O., M.P.H., Assistant Professor of Neurology at Drexel College of Medicine and Director of Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute. “Many people experience significant disruption in their daily activities due to OFF and dyskinesia. As a result, patients will often withdraw from social activities and experience a more significant emotional impact than we may realize. It’s important for people with Parkinson’s and their care partners to be proactive and start the conversation about motor complications with their doctors. We can help patients identify OFF periods and dyskinesia, and ways to maximize good ON time to make the most of their day.”

Key survey findings

  • PD motor complications are common with 76% (n=591) of respondents reporting OFF and 51% (n=398) reporting dyskinesia; 48% (n=368) of respondents reported experiencing both OFF and dyskinesia.
  • Despite the frequency of motor complications 78% of people with Parkinson’s and care partner respondents report an incomplete understanding of OFF and dyskinesia and their relationship to levodopa.
  • Importantly, for respondents who experience motor complications, they happen often. Between 86% and 90% reported the presence of these problems daily and over 60% of respondents changed plans and activities due to these PD motor complications.
  • Ultimately, for many respondents, PD motor complications were found to be unpredictable, make social interactions difficult, and lead to feelings of loneliness and isolation.

The survey was conducted online with the PMD Alliance membership and included 775 respondents, comprising 527 people with Parkinson’s and 248 care partners. Questions included basic demographic and disease state information, presence and frequency of OFF or dyskinesia, and their impact on social interactions and activities.

“The more we understand the true impact and prevalence of PD motor complications, the better we can serve people living with this disease stay socially and physically active,” said Adrian Quartel, M.D., Chief Medical Officer, Adamas. “These data highlight the widespread burden and impact of OFF and dyskinesia in daily living. While many studies are typically confined to specific clinic populations, this survey is unique since PMD Alliance is a national advocacy organization with broad reach whose respondents better reflect the diversity within the community.”

About Parkinson’s disease, OFF and dyskinesia

Parkinson’s disease (PD) is a progressive, neurodegenerative disorder caused by the gradual loss of brain cells that produce the neurotransmitter dopamine and affects approximately one million people in the United States. Dopamine decline in the brain results in a wide range of motor (movement-related) and non-motor symptoms. As the disease progresses, people taking levodopa-based therapy are likely to experience reemergence or sudden return of stiffness, rigidity and tremors, referred to as OFF episodes between medication doses, that may be unpredictable. The primary treatment for PD is with levodopa; however, over time levodopa may lead to involuntary, uncontrolled movements known as dyskinesia. The abrupt and unpredictable transitions between episodes of dyskinesia, normal movement, and OFF lead to considerable impact on patients’ lives.

About Parkinson & Movement Disorder Alliance

Parkinson & Movement Disorder Alliance is an independent, national nonprofit dedicated to providing opportunities for people to learn, live more fully and spark meaningful connections around them. PMD Alliance serves people across the United States and is not affiliated with any medical practice or institution. PMD Alliance is committed to keeping our community safe and healthy. To learn more about the organization visit www.PMDAlliance.org.

About Adamas

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Source: Adamas Pharmaceuticals, Inc.

Media Contacts:

Sarah Mathieson

Vice President of Corporate Communications

510-450-3528

[email protected]

Amanda Nelson

Manager, Public Relations at PMD Alliance

520-664-7951

[email protected]

KEYWORDS: California Arizona United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo

Draganfly Announces Record Revenue in Fourth Quarter and Fiscal 2020 Financial Results

Vancouver, BC., April 19, 2021 (GLOBE NEWSWIRE) — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, is pleased to announce its fourth quarter and fiscal 2020 financial results. Revenue growth for the fourth quarter and the year was driven by a combination of organic growth, the acquisition of Dronelogics Systems Inc. (“Dronelogics”), and sales from COVID-19 screening products.

The financial year 2020 was another milestone year for Draganfly. The Company successfully closed and integrated its Dronelogics acquisition which, as planned, became the driver of the bulk of Draganfly new product revenue sales. The Company’s main custom engineering customer effectively shut down this portion of its business in Q1 2020 primarily due to COVID-19; however, services revenues were successfully offset by other drone services work. 2020 revenues were up 216% year over year coming in at $4,363,511 versus $1,380,427 in the previous year. $645,756 represents custom engineering services work, $630,532 represents drone services work and the balance of revenue was from its hardware sales.

The Company recently added health monitoring and prevention to its product and service offering. Securing some key clients in this business line was key to proving out this new vertical. These clients were important for validation of this new technology, but more importantly, it demonstrated the Company’s ability to evolve and offer products and services that have global applicability.

Financial Highlights – 2020:

● Total revenue for the year ended December 31, 2020, increased by 216.1% to $4.36 million, compared to $1.38 million in 2019.

● As a result of increased product sales and service revenue, the Company’s gross profit increased by $597,973, or 51.5%. As a percentage of sales, gross margin(1) decreased from 84.1% in 2019 to 40.3% in 2020. This shift in gross margin is due to a higher percentage of hardware sales.

● The Company recorded a comprehensive loss of $8,015,709 compared to a comprehensive loss of $11,095,057 in 2019. The decreased loss was largely the result of the lack of listing expense resulting from the 2019 amalgamation and the funds received from the disposition of an investment that had been previously written off.

● The Company’s cash balance on December 31, 2020, was $1.98 million compared to $2.43 million on December 31, 2019.

For the year ended December 31,       2020     2019  
Total revenues   $   4,363,511   $ 1,380,427  
Gross Profit (as a % of revenues)       40.3 %   84.1 %
Net loss       (8,015,813 )   (11,095,057 )
Net loss per share ($)          
– Basic       (0.10 )   (0.23 )
– Diluted       (0.10 )   (0.23 )
Comprehensive loss       (8,015,709 )   (11,095,057 )
Comprehensive loss per share ($)          
– Basic       (0.10 )   (0.23 )
– Diluted       (0.10 )   (0.23 )
Change in cash and cash equivalents       (447,063 )   2,349,954  
Total assets       7,100,567     3,221,783  
Working capital       1,214,371     2,037,906  
Total non-current liabilities       104,885     93,073  
Shareholder’s equity (deficiency)   $   3,848,205   $ 2,191,353  
Number of shares outstanding       86,093,361     69,670,613  

Financial Highlights – Fourth Quarter 2020:

● Revenue for Q4 2020, increased by 202.3% to $1.49 million, compared to $492 thousand for Q4 2019. The substantial increase in revenue is largely due to the Company’s acquisition of Dronelogics and the retail sales and services business that the acquisition brought partially offset by a decrease in custom engineering services due to the downturn caused by COVID-19.

● Gross margin percentage for Q4 2020 was 22.2% compared to 91.4% in Q4 2019. The decrease is due to the sales mix as product sales tend to have a much lower margin than those of custom engineering services.

●Total comprehensive loss for the Q4 2020, was $3.74 million compared to $2.03 million for the same period in 2019. The increase was due to higher office and miscellaneous expenses.

    2020 Q4   2020 Q3   2019 Q4
Revenue $ 1,486,009   $ 1,453,905   $ 491,520  
Cost of goods sold $ (1,155,491 ) $ (893,441 ) $ (42,401 )
Gross profit $ 330,518   $ 560,464   $ 449,119  
Gross margin – percentage   22.2 %   38.5 %   91.4 %
Operating expenses $ (3,359,508 ) $ (2,852,003 ) $ (2,983,115 )
Operating loss $ (3,028,990 ) $ (2,291,539 ) $ (2,533,996 )
Operating loss per share – basic $ (0.04 ) $ (0.03 ) $ (0.04 )
Operating loss per share – diluted $ (0.04 ) $ (0.03 ) $ (0.04 )
Other income (expense) $ (713,885 ) $ 91,228   $ 506,080  
Comprehensive loss $ (3,741,640 ) $ (2,201,543 ) $ (2,027,916 )
Comprehensive loss per share – basic $ (0.05 ) $ (0.03 ) $ (0.03 )
Comprehensive loss per share – diluted $ (0.05 ) $ (0.03 ) $ (0.03 )

Cameron Chell, CEO of Draganfly, said: “We have seen tremendous growth in the first quarter of 2021 around some key initiatives including education, military, security, mining, telehealth, and our 24hr pathogen sequestration and kill sanitizing spray applied via patented drone technology. The Draganfly team is looking forward to continuing to build on those relationships, technologies, and innovations.”

Q4 2020 and Q1 2021 milestones include the following:

● Secured $1 MM flight services contract to deploy EagleEye AI flight services with Windfall Geotek Inc. Windfall Geotek flies mining prospect with magnetometers with data placed into EagleEye and provides recommended targets for mining companies to drill.

● Raised US$16,450,000 million through the issuance of securities under the Company’s Regulation A offering filed with the U.S. Securities and Exchange Commission.

● Entered into an agreement with Southern Alberta Institute of Technology to advance UAV delivery technology, which will include (i) designing, developing, and testing of a cargo system for medical delivery to be ‎mounted on a variety of drones including VTOL rotary and fixed-wing platforms, (ii) developing test protocols, operational procedures, and standards for Beyond Visual ‎Line of Sight medical delivery operation within the framework of ‎Transport Canada, US Federal Aviation Agency, and European ‎Union Aviation Safety Agency procedures and protocols and (iii) developing an operational manual for BVLOS operation of heavy lifting and long ‎endurance RPASS to be used for commercial application under an Air ‎Operator’s Certificate. ‎

● Partnership with Steve Wozniak’s K-12 program Woz ED to be the exclusive supplier of drones to Woz ED’s drone program across its ‎national K-12 curriculum and received orders for the sale of 2,000 drones. To clarify the Company’s news release dated March 2, 2021, the Company entered into a memorandum of understanding with Woz ED with the objective to create the terms and conditions surrounding a business agreement. The memorandum of understanding automatically terminates after 60 days; however, the Company anticipates entering into a definitive agreement with Woz ED during Q2 2021.

● Talladega College implemented Vital Intelligence Smart Vital assessment platform, Vital Signs Assessment Stations, and Social Distancing awareness technologies to be used campus-wide to detect potential symptoms of COVID-19.

● Portage County Sheriff’s Department deployed Vital Intelligence Technology to be used to pre-screen inmates and detainees before bringing them into detention.

● Barrett-Jackson Auction Company implementing Draganfly’s Safely Opening Sites protocol for its March 2021 collector car auction in Scottsdale, AZ. including patented drone technology of the Varigard one-of-a-kind, revolutionary organic sanitizer that provides up to 24-hour of pathogen sequestration and kill-efficacy.

● Design and deliver Vital Intelligence technology into The 517 Group’s Hospitality and Entertainment Service Organization.

● Selected by Coldchain Technology Services, LLC (“Coldchain”) to develop and provide flight services for drone delivery of the COVID-19 vaccine. To clarify the Company’s news release dated December 22, 2020, the Company entered into a letter of intent with Coldchain with the objective to create the terms and conditions surrounding a business agreement for the development of a vaccine delivery payload system and associated flight services. The letter of intent automatically terminates after 90 days; however, the Company anticipates entering into a definitive agreement with Coldchain during Q2 2021.

● Providing engineering and development services for drone-based air support defense system for Integrated Launcher Solutions (“ILS”). To clarify the Company’s news release dated January 21, 2021, the Company entered into a memorandum of understanding with ILS with the objective to create the terms and conditions surrounding a project management and development agreement for the production of ILS’s multi-launching air support defense system. The memorandum of understanding automatically terminates after 60 days; however, the Company anticipates entering into a definitive agreement with ILS during Q2 2021.

● Draganfly selected by Knightscope to integrate mobile Vital Sign Screening technology into its autonomous security robots.

● Issued new delivery drone patent for variable center of gravity vertical take-off and landing aircraft. US Patent No. 10,807,707 is an unmanned aircraft system (UAS) configured for both vertical take-off and landing (VTOL) and fixed-wing flight operations includes forward, and aft wing assemblies mounted to the fuselage, each wing assembly including port and starboard nacelles terminating in motor-driven rotors powered by an onboard control system capable of adjusting rotor speeds.

● Closed an acquisition of assets from Vital Intelligence ‎‎Inc. on March 25, 2021, in consideration for (a) a cash payment of $500,000 with ‎‎$250,000 paid at closing and ‎‎‎$250,000 to be paid on the six-month anniversary date of ‎closing; and (b) ‎6,000,000 units of the ‎‎Company with each unit being comprised of one common share of the Company and one common share ‎‎purchase warrant. The units are subject to ‎‎escrow with 1,500,000 units released at closing and the remainder to be released ‎‎upon the Company reaching certain revenue milestones received from the purchased assets. Each warrant entitles the holder to acquire one common share for a period of 24 ‎months at an exercise price of $2.67 per common share and the Company can accelerate the ‎expiry date of the warrants after one year in the event the underlying common shares ‎have a value of at ‎least 30% greater than the exercise price of the warrants.

All financial information in this press release is prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. The Company will file its consolidated financial statements for the year ended December 31, 2020, and associated management discussion and analysis under the Company’s profile on SEDAR at www.sedar.com.

Note 1: this press release refers to “gross margin” which does not have any standardized meaning prescribed by generally accepted accounting principles in Canada (“GAAP“). Gross margin is defined as gross profit divided by revenue and is often presented as a percent. Draganfly’s management believes that gross margin and other non-GAAP measures provide useful information to investors as it provides them with ‎supplemental measures of the Company’s operating performance and liquidity and thus highlights trends in the Company’s ‎business that may not otherwise be apparent when relying solely on GAAP measures. Management also uses non-GAAP measures and ‎metrics in order to facilitate operating performance comparisons from period to period, to prepare ‎annual operating budgets and forecasts and to determine components of executive compensation. For more information with respect to financial measures which have not been defined by GAAP, including reconciliations to the closest comparable GAAP measure, see the “Non-GAAP Measures and Additional GAAP Measures”‎ section of the Company’s most recent MD&A which is available on SEDAR.

About
Draganfly

Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge software, and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.

For more information on Draganfly, please visit us at www.draganfly.com.
For additional investor information, visit https://www.thecse.com/en/listings/technology/draganflyinc, https://www.otcmarkets.com/stock/DFLYF/overview or https://www.boerse-frankfurt.de/aktie/draganfly-inc.

Media Contact
Arian Hopkins
Email: [email protected]

Company Contact
Cameron Chell, CEO
PH: 310-658-4413
Email: [email protected]

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company’s business, operations and financial condition, the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR website at www.sedar.com. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.



CareCloud Promotes New Leadership to Further Enhance Client Experience and Results

SOMERSET, N.J., April 19, 2021 (GLOBE NEWSWIRE) —

CareCloud, Inc.
 (Nasdaq: MTBC) (Nasdaq: MTBCP), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced the promotion of two leaders within its management team: Daniel Masvidal to Senior Vice President of Client Success, and Dwight Garvin to Senior Vice President of Professional Services. Masvidal and Garvin are working to enhance the client experiences and outcomes as the company’s client roster continues to grow.

“By appointing the brightest in our sector, we ensure our teams are positioned to provide unrivaled solutions and an unmatched client experience,” said Hadi Chaudhry, CEO and President, CareCloud. “Masvidal and Garvin are respected professionals whose impressive backgrounds in healthcare IT will help us ramp up client services to complement our organic growth and sales initiatives.”

As Senior Vice President of Client Success, Daniel Masvidal leads the company’s team of client success professionals, ensuring that CareCloud continues to deliver an exceptional and personalized experience. Previously, Masvidal served as VP of Client Success for CareCloud, where he led the team to support the company’s rapid expansion. In this role, he transformed the client success team to better serve CareCloud’s growing base of larger, complex medical groups by building a scalable infrastructure and processes that enhanced customer loyalty. Masvidal has been an integral part of the CareCloud team since 2013.

“CareCloud has the unique ability to serve small, medium, and large-scale healthcare providers,” said Daniel Masvidal, Senior Vice President of Client Success, CareCloud. “Because our solutions are so comprehensive, we have the privilege of building close-knit relationships across a variety of practice sizes and structures in all 50 states. Combining the right mix of talented professionals with our product portfolio’s world-class infrastructure allows us to boost retention and overall customer satisfaction. I look forward to helping raise the bar on client success even higher.”

As Senior Vice President of Professional Services, Dwight Garvin is responsible for managing the implementations, integrations, education, and enrollment of CareCloud products. His broad experience, ranging from project management to strategic planning, has equipped Garvin to ensure success across CareCloud’s diverse portfolio. Garvin assumes this role after previously serving as the VP of Professional Services for CareCloud, where he was responsible for the successful implementation of CareCloud’s solutions. With seven years of healthcare IT experience working for companies such as athenahealth, Deloitte, and Cerner, Garvin brings valuable industry insight to CareCloud’s client success team.

“This is an exciting time to be involved in the operational success of our clients,” said Dwight Garvin, Senior Vice President of Professional Services, CareCloud. “Our client base is growing, making it imperative that we expand and enrich the implementation services that so many of our new clients rely on.”

About
CareCloud

CareCloud (Nasdaq: MTBC) (Nasdaq: MTBCP) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, telehealth and patient experience management (PXM) at www.carecloud.com.

Follow CareCloud on LinkedInTwitter and Facebook.

SOURCE CareCloud

Company Contact:

Bill Korn
Chief Financial Officer
CareCloud
[email protected]

Investor Contact:

Matt Kreps
Managing Director
Darrow Associates Investor Relations
[email protected]

Media Inquiries:

Kaitlyn Mode
Corporate Communications Manager
CareCloud
[email protected]